US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Vaxart (VXRT.PK) has been ordered to cease new enrollment for its COVID-19 mid-stage trial, a directive stemming from the U.S. Department of Health and Human Services' decision to wind down its vaccine development activities. This action jeopardizes up to $387.2 million in potential milestone payments from Vaxart's $453 million government award and signals a broader shift in U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr.

Analysis

Vaxart has received a stop-work order from the U.S. government for its mid-stage COVID-19 trial, halting all new patient screening and enrollment. This directive, part of a broader U.S. Department of Health and Human Services (HHS) decision to wind down its vaccine development activities, presents a significant financial blow to the company. The order puts at risk up to $387.2 million in milestone payments from a total award valued at $453 million provided by the Biomedical Advanced Research and Development Authority (BARDA). This policy change is being driven by Health Secretary Robert F. Kennedy Jr., who has asserted that certain vaccines are not effective against upper respiratory infections, a claim the report notes was made without scientific evidence. The development signals a material shift in U.S. public health funding priorities, introducing substantial regulatory and political risk for biotech firms like Vaxart that are dependent on government contracts to advance their clinical programs. While Vaxart will continue monitoring currently enrolled participants, the halt to new enrollment effectively stalls the progress of its oral COVID-19 vaccine candidate.

Key Decisions for Investors

• Investors should recognize the termination of the BARDA contract as a major negative catalyst, directly impacting Vaxart's potential revenue stream and its ability to fund the advancement of its oral vaccine candidate without seeking alternative financing.
• The policy shift under HHS Secretary Robert F. Kennedy Jr. introduces a significant new layer of political and regulatory risk for vaccine developers, warranting a portfolio review for exposure to companies reliant on U.S. government health contracts.
• Given the halt of a key mid-stage trial and the associated loss of up to $387.2 million in funding, it is prudent for investors to re-evaluate Vaxart's intrinsic value and monitor for company announcements regarding its revised clinical and funding strategy before initiating or adding to a position.